[1] Kulik L, El-Serag H. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2019, 156:477-491.
[2] Endo K, Kuroda H, Oikawa T, et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate -stage hepatocellular carcinoma. Scand J Gastroenterol, 2018, 53:1575-1583.
[3] Attia N, Othman M. Transcatheter arterial chemoembolization of hepatocellular carcinoma in patients with celiac axis occlusion using pancreaticoduodenal arcade as a challenging alternative route. Eur J Radiol Open, 2017, 4:53-57.
[4] Miyayama S, Yamashiro M, Nagai K, et al. Evaluation of tumor recurrence after superselective conventional transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of computed tomography and gadoxetate disodium enhanced magnetic resonance imaging. Hepatol Res, 2016, 46: 890-898.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 临床肝胆病杂志, 2011, 20:929-946.
[6] Crummy A, Strother C, Mistretta C. The history of digital subtraction angiography. J Vasc Interv Radiol, 2018, 29:1138-1141.
[7] Chapiro J, Duran R, Lin M, et al. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol, 2015,25:1993-2003.
[8] Liu Q, He C, Zhou Y, et al. Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol, 2016, 22:3242-3251.
[9] Wang C, Wey K, Mol R, et al. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev, 2015,16:3595-3604.
[10] 高永广, 郝敬明, 李光超,等. 能谱CT估算原发性肝癌其血供比例的初步研究. 临床放射学杂志, 2014, 33:1198-1200. |
